Histological changes following the administration of two different chondroitin sulfate products in experimental osteoarthritis models in rats

• Authors: Dmitriy Nosivets , Eulalia Montell , Valentine Opryshko
• Languages of publication: EN

Abstracts

EN

Introduction. Osteoarthritis (OA) is generally a progressive disease that affects synovial joints, resulting in abnormalities to articular cartilage subchondral bone, synovium, and adjacent soft tissues. Aim. The purpose of this work was to examine the histological changes in knee cartilage and bone following the administration of two different chondroitin sulfate products in two experimental OA models in rats. Material and methods. OA was induced in rats by either a single injection of mono-iodoacetate or four once-weekly injections of dexamethasone. 70 adult rats were included: 30 received mono-iodoacetate, 30 received dexamethasone and the 10 remaining controls received no injection. Samples of knee bone and cartilage were then analyzed histologically. Results. Animals with OA that received CS had significantly less inflammation, improved motor activity, and better analgesia compared with those that did not receive CS, with little difference between products. Histologically, both products reduced the signs of OA and resulted in the activation of regenerative processes of cartilage and bone and stimulation of proliferation and formation of amorphous material. Conclusion. These results substantiate the importance of using high-quality pharmaceutical-grade CS to ensure optimal efficacy and safety of the final product in patients with OA

Keywords

EN

chondroitin sulfate; chondroprotection; osteoarthritis

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2021
• Issue: 1
• Pages: 23-32

Contributors

author

Dmitriy Nosivets

• Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine, Dnipro, Ukraine

author

Eulalia Montell

• Pre-Clinical R&D Area, Pharmascience Division, Bioibérica, S.A.U., Barcelona, Spain

author

Valentine Opryshko

• Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine, Dnipro, Ukraine

Identifiers

DOI

10.15584/ejcem.2021.1.4